title: Circulating autoantibodies to recombinant lipocortin-1 in asthma.
abstract: One of the postulated mechanisms of corticosteroid action is through the de novo synthesis and release of lipocortins. We assayed circulating antibodies to lipocortin-1 in sera obtained from normal (n = 67) and asthmatic (n = 57) subjects using an ELISA technique. Asthmatic subjects with a wide range of severity, with the mildest needing only occasional inhaled beta-agonist therapy to the most severe needing maintenance oral corticosteroid treatment, were recruited from our Asthma Clinic and classified into five categories according to the need of therapy. Median values of IgM and IgG lipocortin-1 antibody for normal subjects were 19.3 (interquartile range (r) = 11.0-30.4) and 16.9 (r = 10.54-29.4) ELISA units (EU) ml-1 respectively. These levels were significantly elevated in asthmatic subjects: IgM = 43.9 EU ml-1 (r = 31.7-64.5) and IgG = 29.0 EU ml-1 (r = 21.2-44.7) (P less than 0.001). There was no significant relationship between the levels of lipocortin antibody and the clinical severity of asthma. Asthmatics with significantly raised levels of antibody were found within all five categories of severity. We conclude that the level of this antibody is not related to severity of asthma, to previous or current corticosteroid therapy or to the development of corticosteroid resistance.
authors.affiliation: Department of Thoracic Medicine, National Heart and Lung Institute, London, U.K.
authors.forename: K F
authors.initials: KF
authors.lastname: Chung
authors.forename: M R
authors.initials: MR
authors.lastname: Podgorski
authors.forename: N J
authors.initials: NJ
authors.lastname: Goulding
authors.forename: J L
authors.initials: JL
authors.lastname: Godolphin
authors.forename: P R
authors.initials: PR
authors.lastname: Sharland
authors.forename: B
authors.initials: B
authors.lastname: O'Connor
authors.forename: R J
authors.initials: RJ
authors.lastname: Flower
authors.forename: P J
authors.initials: PJ
authors.lastname: Barnes
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017302:Annexins; D001249:Asthma / Q000188:drug therapy / Q000276:immunology*; D001323:Autoantibodies / Q000032:analysis*; D002135:Calcium-Binding Proteins / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D008297:Male; D008875:Middle Aged; D010740:Phospholipases / Q000037:antagonists & inhibitors*; D011994:Recombinant Proteins
chemical_list: D000305:Adrenal Cortex Hormones; D017302:Annexins; D001323:Autoantibodies; D002135:Calcium-Binding Proteins; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D011994:Recombinant Proteins; D010740:Phospholipases